Teleflex Incorporated (NYSE:TFX) Receives Average “Buy” Rating from Brokerages
Shares of Teleflex Incorporated (NYSE:TFX – Get Rating) have earned a consensus rating of “Buy” from the fifteen analysts who currently cover the company, reports Marketbeat Ratings. One equity research analyst rated the stock with a sell rating, three assigned a hold rating and eight issued a buy rating on the company. The 1-year average price target among analysts who have reported on the stock in the past year is $388.46.
Several brokerages have recently weighed in on TFX. Bank of America assumed coverage for Teleflex shares in a Monday, May 9 research report. They set a “neutral” rating and a price target of $315.00 for the company. Zacks Investment Research moved Teleflex shares from a “hold” rating to a “sell” rating and set a target price of $373.00 for the stock. in a research note from Friday, April 1. Piper Sandler raised her price target on Teleflex shares from $320.00 to $335.00 in a Thursday, February 24 research report. Truist Financial cut its price target on Teleflex shares from $370.00 to $340.00 in a Friday, April 29 research report. Finally, Morgan Stanley cut its price target on Teleflex shares from $383.00 to $378.00 and set an “equal weight” rating on the stock in a Friday, Feb. 25 report.
Shares of TFX traded down $1.88 in Friday trading, hitting $286.81. The company’s shares had a trading volume of 2,232 shares, compared to an average volume of 490,881. Teleflex has a 52-week low of $256.77 and a 52-week high of $428.36. The company has a current ratio of 2.28, a quick ratio of 1.53 and a debt ratio of 0.46. The company has a fifty-day moving average of $320.39 and a 200-day moving average of $324.03. The company has a market capitalization of $13.45 billion, a PE ratio of 28.35, a P/E/G ratio of 1.91 and a beta of 1.13.
Teleflex (NYSE:TFX – Get Rating) last released its results on Thursday, April 28. The medical technology company reported EPS of $2.88 for the quarter, beating consensus analyst estimates of $2.72 by $0.16. Teleflex had a return on equity of 17.24% and a net margin of 17.31%. The company posted revenue of $641.70 million for the quarter, compared to $631.89 million expected by analysts. In the same quarter of the previous year, the company had earned earnings per share of $2.87. The company’s revenue increased 1.2% year over year. As a group, research analysts predict Teleflex will post EPS of 13.98 for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 15. Shareholders of record on Monday, May 16 will receive a dividend of $0.34. The ex-dividend date is Friday, May 13. This represents an annualized dividend of $1.36 and a dividend yield of 0.47%. Teleflex’s dividend payout ratio (DPR) is 13.22%.
Several large investors have recently bought and sold shares of TFX. City State Bank bought a new position in Teleflex during the fourth quarter for a value of approximately $27,000. Allworth Financial LP increased its position in Teleflex shares by 144.4% during the fourth quarter. Allworth Financial LP now owns 110 shares of the medical technology company valued at $36,000 after acquiring 65 additional shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in Teleflex shares by 62.9% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 114 shares of the medical technology company valued at $38,000 after acquiring 44 more shares in the last quarter. Aquire Wealth Advisors LLC acquired a new equity stake in Teleflex during the fourth quarter valued at approximately $38,000. Finally, Spire Wealth Management increased its holding in Teleflex shares by 3,900.0% in the fourth quarter. Spire Wealth Management now owns 120 shares of the medical technology company valued at $40,000 after buying 117 more shares last quarter. 92.21% of the shares are currently held by hedge funds and other institutional investors.
About Teleflex (Get a rating)
Teleflex Incorporated designs, develops, manufactures and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that include Arrow-branded catheters, catheter tip navigation and positioning systems, and intraosseous access systems for delivery of intravenous therapies, pressure measurement artery and collection of blood samples via a single puncture site.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Teleflex right now?
Before you consider Teleflex, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off...and Teleflex wasn’t on the list.
Although Teleflex currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here